RxDoctor Payments Data

Joyce Wei, NP

Family · McKinney, TXNPI 1629463013

Payments from drug & device makers

$1,202in general payments, 2019–2025

Across 35 payments — averaging $34.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$228
  • Exact Sciences$212
  • AstraZeneca$132
  • Edwards Lifesciences$131
  • AbbVie$125
  • Atricure, Inc.$105
  • plus $268 from 8 others

What the payments were for

  • Food & beverage$1,202100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,202 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$79,307
Medicare patients
208
Services billed
1,446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$77,728
MounjaroTirzepatide16$30,678
EliquisApixaban14$20,638
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$6,019
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$3,523
Rosuvastatin Calcium164$2,815
Levothyroxine Sodium195$1,794
Gabapentin67$1,639
Atorvastatin Calcium125$1,485
SynthroidLevothyroxine Sodium24$1,194
Lisinopril87$1,130
Fluticasone Propionate34$975
Montelukast Sodium62$966
Ezetimibe43$906
Omeprazole73$889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$228$77,72846 claims
PfizerEliquis$24$20,63814 claims
AbbVieSynthroid$125$1,19424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in McKinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →